New Head-to-Head Data Show TALTZ® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis

    NEXT STORY
    Vir Biotechnology Announces Pricing of Initial Public Offering
    PREV STORY
    GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aravive Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Corporate Updates

    author_avatar
    NASDAQ Market News

    Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology

    author_avatar
    NASDAQ Market News

    Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC

    PDUFA Action Date Set for September 28, 2018BRIDGEWATER, N.J., May 16, 2018 (GLOBE NEWSWIRE) ...

    author_avatar
    NASDAQ Market News